KEYTRUDA + chemo approved in the EU for patients with primary advanced/recurrent endometrial carcinoma and + chemoRT for patients with Stage III-IVA locally advanced cervical cancer October 29, 2024
IGCS 2024: Positive Updated RAMP 201 Data for Avutometinib & Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer Presented October 22, 2024
FAILED TRIAL: Ph 2 study of TG4001 + avelumab vs avelumab in patients with R/M HPV16-positive cervical and anogenital tumors did not meet the primary objective of PFS improvement October 15, 2024
First patient enrolled in Ph 1/2a clinical trial for Lenti-HPV07 against oropharyngeal and cervical cancers October 15, 2024
First Patient Dosed in Ph 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients October 15, 2024
Cartherics raises over $15 Million in oversubscribed private financing round to advance cell therapy programs October 8, 2024
36-Month OS Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation Announced October 8, 2024
FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers October 8, 2024
Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer September 24, 2024
Positive EU CHMP Opinions for KEYTRUDA Regimens as Treatment for Patients With cervical cancer and endometrial carcinoma September 24, 2024
Two Patients Now Exceeding 1 Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial September 22, 2024
Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers September 3, 2024
Lynparza and Imfinzi combination approved in the EU for patients with MMR-proficient advanced or recurrent endometrial cancer August 22, 2024
11.1 Month Increase in OS in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001 in OVATION 2 Ph 2 trial Announced August 6, 2024
FDA expands Jemperli (dostarlimab) + chemo approval to all adult patients with primary advanced or recurrent endometrial cancer with demonstrated OS benefit August 6, 2024
Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with MMR-proficient advanced or recurrent endometrial cancer July 9, 2024
Database Lock announced for Ph 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer July 1, 2024
Stenoparib Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer in Ph 2 clinical trial July 1, 2024
